Aseptically Prepared Systemic Anti-Cancer Therapy Medicines

Description

This framework agreement is for the supply of a range of aseptically prepared, batch manufactured systemic anti-cancer therapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific systemic anti-cancer therapy drugs and medicines used in CIVAs.

Key facts

Procedure

Open procedure

Framework agreement

Yes — a framework or dynamic purchasing system, not a single contract

Lots

4

Contact

Customer Care

customercare@htepg.com

01268 524900

Value basis

one ceiling restated across the appointed suppliers, not separate sums

Contract period

1 Dec 2026 → 30 Nov 2034

Awarded suppliers

• Baxter Healthcare Ltd · GB-COH-00461365 · UKH17, GB
• Sciensus Pharma Services Limited · GB-COH-02759609 · UKI32, GB
• ITH Pharma Ltd · GB-COH-06569105 · UKI31, GB
• Lloyds Clinical Ltd · GB-COH-02764914 · UKH35, GB
• Qualasept Limited · GB-COH-05548345 · UKK15, GB
• Quantum Pharmaceutical Limited · GB-COH-05240304 · UKC14, GB

Bid competition

Who else bid, as published on the notice. A bid is an offer, not money paid: nothing in this section is an award, and a firm named here was not necessarily paid anything.